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ABSTRACT 
  
The presence of telomerase activity has been analyzed in almost all tumor types and 
tumor-derived cell lines. However, there are very few studies that focus on the presence 
of telomerase activity in bone tumors, and most of them report analysis on very few 
samples or bone-derived cell lines. The objective of this study was to analyze the 
telomere length and telomerase activity in primary tumors and metastatic lesions from 
pediatric osteosarcoma and Ewing’s sarcoma patients. The presence of telomerase 
activity was analyzed by the telomeric repeat amplification protocol assay, and the 
telomere length was measured by Southern blot. Results were related to survival and 
clinical outcome. Telomerase activity was detected in 85% of the bone tumor 
metastases (100% Ewing’s sarcomas and 75% osteosarcomas) but only in 12% of the 
primary tumors (11.1% osteosarcomas and 12.5% Ewing’s sarcomas). Bone tumor 
tissues with telomerase activity had mean telomere lengths 3 kb shorter than those with 
no detectable telomerase activity (p = 0.041). The presence of telomerase activity was 
associated with survival (p = 0.009), and longer event-free survival periods were found 
in patients who lacked telomerase activity compared with those who had detectable 
telomerase activity levels in their tumor tissues (p = 0.037). The presence of longer 
telomeres in primary pediatric bone tumors than in metastases could be indicative of 
alternative mechanisms of lengthening of telomeres for their telomere maintenance 
rather than telomerase activity. Nevertheless, the activation of telomerase seems to be a 
crucial step in the malignant progression and acquisition of invasive capability of bone 
tumors.  
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INTRODUCTION 
 
Human telomeres are composed of (TTAGGG)n tandem repeats, and they protect 
eukaryotic chromosomes, preventing their degradation, fusion, and recombination (1, 
2). With each cell division, there is a telomere loss of 50 to 200 bp as a result of the 
inability of the DNA-polymerase to completely replicate the 3' end of the lagging strand 
(the “end-replication” problem) (3), and this progressive loss of noncoding genetic 
material leads to cell senescence when a critical telomere length is reached. It has been 
postulated that this growth arrest is mediated by the TP53 or RB1 tumor suppressor 
gene pathways in response to DNA damage (4, 5). 
 
Telomerase is a ribonucleoprotein composed of three sub-units (6–8) that compensates 
for telomere loss by adding telomeric repeats onto chromosomal ends, thus lengthening 
the proliferative cell life (9). Telomerase activity directly depends on its catalytic 
subunit (hTERT) (10, 11), and it has been detected in 50% to 100% of all tumor types 
and in 70% of cells immortalized in vitro but not in most normal somatic tissues (12, 
13). Some telomerase-negative cell lines immortalized in vitro possess very long and 
heterogeneous telomeres as the result of alternative mechanisms for lengthening 
telomeres (ALT) (14). Some of these telomerase-negative cell lines are the 
osteosarcoma-derived cell lines Saos2, U-2 OS, and G-292 (15). 
 
Osteosarcoma is the most frequent bone tumor diagnosed during childhood and 
adolescence, and 10 to 15% of the patients present distant metastases at diagnosis (90% 
lung, 10% other bones). Ewing’s sarcoma is the second pediatric bone tumor in 
frequency; most of them are diagnosed during the second decade of life, and 15 to 20% 
of the patients have metastases at diagnosis (50% lung, 25% other bones, 25% bone 
marrow) (16). 
 
There are scarce and controversial data concerning the telomere maintenance 
mechanisms of pediatric bone tumors, and the objective of this study was to analyze the 
presence of telomerase activity and the telomeric restriction fragment (TRF) lengths in 
primary and metastatic tissue samples from Spanish Ewing’s sarcoma and pediatric 
osteosarcoma patients. 
 
 
 
METHODS 
 
Samples and patients 
 
We have included samples from 17 osteosarcoma and 13 Ewing’s sarcoma pediatric 
patients who were treated and followed at the Department of Pediatrics of the 
University Clinic of Navarra (Spain) by standard protocols (17, 18). The investigation 
was approved by the Ethics Committee of the University Hospital, and informed 
consent was obtained from all of the participants or their parents. Tissues were 
classified according to their origin in primary tumors (biopsies; 12 osteosarcoma and 13 
Ewing’s sarcoma samples) and metastases (10 from osteosarcomas and seven from 
Ewing’s sarcomas) and frozen at —80°C until use. 
 
 
 
Telomeric repeat amplification protocol assay 
 
Protein extraction by CHAPS buffer (3-[(3-Cholamidopropyl)dimethyl-ammonio]-1-
propanesulfonate) followed by the telomeric repeat amplification protocol (TRAP) 
assay was performed as described previously (19, 20). In brief, 50–100 mg of each 
tissue specimen was thawed on ice and homogenized in 300 µL of lysis buffer [0.5% 
CHAPS, 10 mM of Tris-HCl (pH 7.5), 1 mM of MgCl2, 1 mM of EGTA, 5 mM of 2-
mercaptoethanol, 10% glycerol]. After a 30-min incubation on ice, the lysate was 
centrifuged at 16,000 X g and the supernatant was recovered and used for protein 
quantification. 
 
The protein concentration of lysates was measured using the MicroBCA Kit (Pierce, 
Rockford, IL, U.S.A.). The assay uses PCR to amplify the products of the telomerase-
catalyzed extension of the oligonucleotide primer telomerase substrate. To exclude 
interference with the TRAP assay by telomerase or PCR inhibitors, we included two 
different protein concentrations (1 µg/µL and 5 µg/gL) for each sample and a third 
reaction with RNAse Out (GibcoBRL, Prat del Llobregat, Barcelona). 
 
The PCR procedure was performed in a GeneAmp PCR system 2400 (Perkin-Elmer, 
Wellesley, MA, U.S.A.) with an initial step of 2 min at 92°C followed by 25 cycles of 
95°C for 30 s, 50°C for 30 s, and 72°C for 30 s. The PCR amplification products were 
resolved by 8% denaturing (7 M of urea) polyacrylamide gels (19:1) for 1 h at 20 mA. 
Gels were exposed and analyzed in a phosphoimager (BioRad, Hercules, CA, U.S.A.). 
 
 
TRF length analysis 
 
TRF length was measured in 25 primary tumors and 17 metastatic tissues and in paired 
peripheral blood samples by Southern blotting, using the telomere complementary probe 
(TTAGGG)4 (21). In brief, 5 µg of genomic DNA was digested with HinfI (New 
England Biolabs, Beverly, MA, U.S.A.) and subjected to electrophoresis in 0.8% 
agarose gels at 35 V for 22 h. Gels were then denatured and neutralized. DNA was 
transferred to a nylon membrane, and blots were hybridized with 1 to 1.5 X 106 cpm/mL 
of the [y-32P]dATP end-labeled [y-32P-(TTAGGG)4] telomeric probe at 50°C for 16 h, 
followed by three consecutive washes with 4X salt sodium citrate and 0.5% SDS 
solution at 50°C for 40, 30, and 15 min. The telomere length was estimated by 
comparison with a molecular weight marker and analyzed with the Quantity One 4.0.3 
phosphoimager software (BioRad). 
 
The mean TRF length was calculated using the following formula:  
Mean = Σ(ODi)/ Σ (ODi/Li), where OD is the intensity of hybridization signal and L is 
the length, in Kb, at the gel point i (22). 
 
 
Statistical analysis.  
 
The quantitative variables were com-pared by the t test (upon fulfillment of the 
normality criteria), and the presence of telomerase activity in the different tumor tissue 
types was compared by χ2 with Yates modification for small numbers if needed. The 
differences were considered statistically significant when their associated probability 
was p ≤ 0.05. The statistical analysis was performed using the Statistical Package for the 
Social Sciences program, version 10.0 (SPSS, Chicago, IL, U.S.A.). 
 
 
RESULTS 
 
Telomerase activity 
 
In the TRAP assay, the presence of telomerase activity yields a 6-bp ladder as a result of 
the synthesis of the telomeric hexanucleotide. Each sample was assayed at two different 
protein concentrations (1 µg/µL and 5 µg/µL) and with RNAse as a negative control. 
 
The 30 tissue samples analyzed were classified according to their origin in primary 
tumors and metastases and according to their diagnosis in osteosarcomas and Ewing’s 
sarcomas. The presence of telomerase activity in metastases was statistically increased 
compared with primary tumors, both in osteosarcomas and in Ewing’s sarcomas (Table 
1). All of the Ewing’s sarcoma metastases showed detectable telomerase activity 
compared with 12.5% of the primary tumors. In the case of the osteosarcoma tissues, 
75% of metastases had detectable activity, compared with 11.1% of the primary tumors 
(Table 1). The primary tumors that showed telomerase activity, one osteosarcoma and 
one Ewing’s sarcoma, corresponded to patients who presented metastases at the time of 
diagnosis, both dying in < 2 years after diagnosis. 
 
The presence of telomerase activity in tumor tissues was associated with survival, and 
75% of the patients who showed activity in their tissues died, whereas 76.5% of the 
patients who lacked telomerase activity are still alive (p = 0.009; Table 2). We detected 
significantly longer event-free survival periods in patients who lacked telomerase 
activity compared with those who had detectable telomerase levels in their tumor tissues 
(p = 0.037). That the development of metastasis is an independent poor prognostic 
factor in pediatric bone tumors strongly suggests that the association between mortality 
and telomerase activity is related to the presence of this activity being detected almost 
exclusively in metastatic lesions. 
 
 
TRF length  
 
Hybridization with the telomeric probe generates a smear that covers all of the telomeric 
lengths within the sample. In general, metastatic tissues had statistically shorter TRFs 
than primary tumors (p = 0.026). Several of the primary tumors had a mean TRF length 
longer than 15 kb, whereas some of the metastases did not reach 5 kb. 
 
Telomere length was compared in 25 primary tumors and 17 metastases to peripheral 
blood samples from the same patients by a t test for paired samples (Fig. 1). Primary 
tumors had mean TRF lengths (11.4 kb) significantly longer (p = 0.032) than paired 
peripheral blood samples (9.7 kb), but no differences were found when comparing 
metastases (8.8 kb) with peripheral blood samples (p = 0.146). 
 
Bone tumor tissues with telomerase activity had mean TRF lengths 3 kb shorter than 
those with no detectable telomerase activity (p = 0.041). Nevertheless, the detection of 
telomerase activity almost exclusively in metastases does not allow us to determine 
whether the differences in TRF length are due to the sample type (metastases or primary 
tumors) or to the presence of telomerase activity. 
 
 
 
DISCUSSION 
 
Telomerase activity has been detected in 85 to 90% of all tumor types analyzed to date, 
but primary pediatric bone tumors seem to develop mechanisms other than telomerase 
to maintain their telomere length during the initial steps of their carcinogenesis; 
nevertheless, they need to activate telomerase for progression and full malignization. 
The presence of telomerase activity in 87% of osteosarcoma and 100% of Ewing’s 
sarcoma metastatic samples compared with 11% of osteosarcoma and 12.5% of Ewing’s 
sarcoma primary tumors agrees with the results obtained by other authors (23–25). 
Nevertheless, there are several other reports in the literature that describe presence of 
telomerase activity in 85 to 100% of primary osteosarcomas (26, 27). In addition, 
Sangiorgi et al. (27) detected an association between high level of telomerase activity 
and better outcome in the seven osteosarcomas analyzed, which contrasts both with our 
findings and with their own in other bone and soft tissue tumors. In our opinion, the 
discrepancies between different reports may be due to the low number of patients 
included, which makes it very difficult to establish relationships with clinical 
parameters, as well as the inclusion of heterogeneous osteosarcoma patients and even 
adults in the same analysis. 
 
The difference between the level of telomerase activity detected in primary and 
metastatic tumor tissues could indicate that the activation of telomerase is a hallmark of 
the full malignant phenotype of pediatric bone tumors. The involvement of telomerase 
in the malignization process could be explained by an evolution in the mechanism of 
telomere maintenance during carcinogenesis, from ALT mechanisms to the activation of 
telomerase, or by an earlier activation of telomerase. 
 
Several publications support the idea that telomerase is activated in the later steps of 
carcinogenesis (28–30). In view of the putative role for telomerase on carcinogenesis 
proposed by other authors for other tumor types (30), one could hypothesize that 
alterations in tumor suppressor genes, such as TP53 or RB1, or in genes involved in the 
telomeric complex, such as TRF1 and TRF2, could favor the ALT mechanisms (Fig. 2, 
pathway 1). 
 
The tumor cell lines that use ALT mechanisms are characterized by the presence of 
heterogeneous TRF lengths. It has been demonstrated that the ALT mechanisms can 
coexist with telomerase activity in cell cultures and tumors (31, 32). The presence of 
extremely short TRFs in some chromosomes is enough for the activation of telomerase, 
which could protect the cell from chromosome fusion, terminal deletions, and other 
chromosomal aberrations (33). Once telomerase has replaced the lost telomeric 
repetitions, the cell can keep on proliferating until it achieves the invasive and 
metastatic capability (Fig. 2, pathway 2). Nevertheless, the presence of telomerase 
activity in preinvasive benign tissues in several carcinomas (prostate, liver) (34, 35) 
indicates that early activation of telomerase also exists and that telomerase cooperates in 
the malignant progression process. 
 
Another possibility is that inside the tumor mass, a scarce number of cells could escape 
from senescence and crisis by the activation of telomerase when their telomeres become 
critically shortened. Those cells could then go on to generate the metastatic lesions (Fig. 
2, pathway 3). From the results obtained in this study, it could be inferred that ALT 
mechanisms are less effective than telomerase in the malignant progression, which gives 
justification to the fact that telomerase-positive cells are responsible for the appearance 
of metastases. 
 
The existence of these primary telomerase-positive cells could be detected by in situ 
hybridization but, because of the scarce amount of tissue, this verification could not be 
done in our study. Nevertheless, the presence of smears in the low molecular weight 
region of the blots may indicate the presence of such cells in the primary tumors that 
were not detectable in the background of the more abundant cells with longer TRFs. 
 
This second hypothesis seems to be the most logical for bone tumors. If this hypothesis 
is right, then pediatric bone tumors would be generated by ALT mechanisms as a result 
of any genetic alteration that induces this pathway for the maintenance of the telomere 
length. In a recent study, overexpression of cyclin D1 increased the proliferative life of 
normal keratinocytes, and, when the TP53 gene was also inactivated, the authors 
obtained immortal cells with very heterogeneous TRF, which lacked telomerase activity 
(36). In fact, a recent report by Ulaner et al. (25) concluded that ALT is the predominant 
mechanism for telomere maintenance in osteosarcomas and that this may be due to the 
lower cell turnover that is present in mesenchymal tissues compared with carcinomas, 
which may be associated with stronger physiologic repression of telomerase expression 
(37). 
 
Maybe one of those mechanisms or one of the genetic alterations that induce the 
activation of ALT mechanisms in osteosarcomas involves the RB1 gene, which has 
been associated with longer TRF in retinoblastoma and in immortal cell lines (15). In 
our series of tumor tissue samples, we found that all of the samples with loss of 
heterozygosity at RB1 (4 of 21) (38) had TRF 5 kb longer than those with normal RB1 
(data not shown). 
 
The difference in TRF length between telomerase-negative and -positive samples (p = 
0.041) suggests that telomerase is activated when the telomere length becomes critical, 
to ensure the proliferation levels required for immortalization. However, it could also 
indicate that ALT mechanisms generate longer telomeres than telomerase. Data to 
support this theory have been published by other authors mainly in tumor-derived cell 
lines that lack telomerase activity as well as those derived from osteosarcomas (39, 40). 
There was no detectable difference in the TRF length or telomerase activity levels 
between osteosarcomas and Ewing’s sarcomas. This indicates that both tumor types 
could be using the same mechanisms for telomere maintenance. 
 
The cytogenetic alterations responsible for the development of 95% Ewing’s sarcomas 
are well known, but the carcinogenesis of osteosarcomas requires further investigation 
because, to date, neither genetic nor cytogenetic alterations have been described that are 
present in the vast majority of these tumors. The detection of telomerase activity in 
almost all of the metastatic tissues analyzed makes telomerase an attractive target for 
the discovery of new anticancer agents focused on the arrest of bone tumor progression. 
In fact, several anti-telomerase or telomere-interacting molecules are already being 
widely investigated (41). 
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Table 1. Telomerase activity in tissue samples from pediatric bone tumors             
in relationship to tissue origin 
Tumor type Sample type No. with TA +/No. analyzed Probability* 
Osteosarcoma Primary tumor 1/9  
 metastases 6/8  
Ewing’s sarcoma Primary tumor 1/8  
 metastases   
 metastases 5/5  
Total Primary tumor 2/17 p < 0.001 
 metastases 11/13  
TA, telomerase activity. 
* χ2 test with continuity correction. 
 
 
 
 
 
 
 
Table 2. Telomerase activity in tumor samples from osteosarcoma and               
Ewing’s sarcoma patients in relationship to survival 
Tumor type Survival TA+ TA− Probability* 
Osteosarcoma Alive (n = 1) 2 9  
 Dead (n = 6) 5 1  
Ewing’s sarcoma Alive (n = 5) 2 3  
 Dead (n = 6) 4 2  
Total Alive (n =16) 4 (23.5%) 12 (76.5%) p = 0.009 
 Dead (n = 12) 9 (75%) 3 (25%)  
* χ2 test with continuity correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Southern blot showing the TRF lengths of samples from four pediatric 
osteosarcomas. Each three lanes correspond to different samples from the same patient. 
B, blood; R, tumoral resection; M, metastasis. 
 
 
 
 
 
Figure 2. Models for bone tumor progression. (Pathway 1) Activation of ALT 
mechanisms as a result of loss of heterozygosity at RB1 or mutations in telomeric 
proteins. (Pathway 2) Later telomerase activation in several cells as a result of the 
accumulation of mutations in regulator genes or chromosomal aberrations. (Pathway 3) 
Earlier activation of telomerase arising from critical telomere shortening in bone tumor 
progression. Reprinted from Kim et al. (30), with permission from Elsevier. 
 
 
 
 
